1. Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development. (April 2008) Authors: Urtishak, Sandra; Alpaugh, R Katherine; Weiner, Louis M; Swaby, Ramona F Journal: Biomarkers in medicine Issue: Volume 2:Number 2(2008) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P16 status and choice of chemotherapy in the KEYNOTE-040 study – Authors' reply. Issue 10206 (12th October 2019) Authors: Cohen, Ezra E W; Soulières, Denis; Swaby, Ramona F; Harrington, Kevin J Journal: Lancet Issue: Volume 394:Issue 10206(2019) Page Start: 1323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Issue 10167 (12th January 2019) Authors: Cohen, Ezra E W; Soulières, Denis; Le Tourneau, Christophe; Dinis, José; Licitra, Lisa; Ahn, Myung-Ju; Soria, Ainara; Machiels, Jean-Pascal; Mach, Nicolas; Mehra, Ranee; Burtness, Barbara; Zhang, Pingye; Cheng, Jonathan; Swaby, Ramona F; Harrington, Kevin J Journal: Lancet Issue: Volume 393:Issue 10167(2019) Page Start: 156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. (14th May 2020) Authors: Harrington, Kevin J; Soulières, Denis; Le Tourneau, Christophe; Dinis, Jose; Licitra, Lisa F; Ahn, Myung-Ju; Soria, Ainara; Machiels, Jean-Pascal H; Mach, Nicolas; Mehra, Ranee; Burtness, Barbara; Ellison, Misoo C; Cheng, Jonathan D; Chirovsky, Diana Romana; Swaby, Ramona F; Cohen, Ezra E W Journal: Journal of the National Cancer Institute Issue: Volume 113:Number 2(2021) Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗